Currently, Geron Corp. [GERN] is trading at $3.33, up 0.30%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The GERN shares have gain 5.05% over the last week, with a monthly amount glided 58.57%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 3, April 2024, Geron to Participate at Upcoming Investor Conferences in April. In a post published today on Yahoo Finance, Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences:.
From an analyst’s perspective:
Geron Corp. [NASDAQ: GERN] stock has seen the most recent analyst activity on March 15, 2024, when Needham reiterated its Buy rating and also boosted its price target to $5 from $4. Previously, Goldman upgraded its rating to Buy on September 12, 2023, and kept the price target unchanged to $4. On March 28, 2023, Goldman initiated with a Neutral rating and assigned a price target of $3 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $5 on October 28, 2022. Robert W. Baird started tracking with a Outperform rating for this stock on November 02, 2021, and assigned it a price target of $4.
This stock has fluctuated between a low of $1.64 and a high of $3.73 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $5.33 within the next 12 months. Geron Corp. [NASDAQ: GERN] shares were valued at $3.33 at the most recent close of the market. An investor can expect a potential return of 60.06% based on the average GERN price forecast.
Analyzing the GERN fundamentals
Trailing Twelve Months sales for Geron Corp. [NASDAQ:GERN] were 0.24M which represents -77.67% decline. Gross Profit Margin for this corporation currently stands at -126.4% with Operating Profit Margin at -818.33%, Pretax Profit Margin comes in at -776.91%, and Net Profit Margin reading is -776.71%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.63 and Total Capital is -0.68. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.24 points at the first support level, and at 3.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.39, and for the 2nd resistance point, it is at 3.46.
Geron Corp. [GERN] reported earnings per share of -$0.09 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.1/share, meaning a difference of $0.01 and a surprise factor of 10.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.08 per share as compared to estimates of -$0.1 per share, a difference of $0.02 representing a surprise of 20.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Geron Corp. [NASDAQ:GERN] is 3.16. Also, the Quick Ratio is 3.16, while the Cash Ratio stands at 0.66. Considering the valuation of this stock, the price to sales ratio is 8159.33, the price to book ratio is 7.32.
Transactions by insiders
Recent insider trading involved O’Farrell Elizabeth G., Director, that happened on Aug 24 ’23 when 6607.0 shares were purchased. Director, O’Farrell Elizabeth G. completed a deal on Aug 24 ’23 to buy 6579.0 shares. Meanwhile, Director LAWLIS V BRYAN sold 35000.0 shares on May 11 ’23.
